Published on Microbicide Trials Network (http://www.mtnstopshiv.org)

Home > MTN-009

MTN-009

Details
Protocol Title: 
Prevalence of HIV-1 Drug Resistance within a Female Screening Population for HIV Prevention Trials
DAIDS Protocol ID: 
10791
Status: 
Closed to Accrual

Protocol Chair(s)

Photini Kiepiela [1] (Protocol Co-Chair)
Urvi Parikh [2] (Protocol Co-Chair)

Email Groups

MTN-009 ACASI [3]
MTN-009 Management [4]
MTN-009 Protocol Deviations [5]
MTN-009 Protocol Team [6]
MTN-009 Publication Committee [7]
Sites
Bothas Hill Clinical Research Site [8]
Isipingo CRS [9]
Overport CRS [10]
Chatsworth CRS [11]
Tongaat CRS [12]
Umkomaas Clinical Research Site [13]
Verulam CRS [14]
Countries
South Africa [15]
Description
MTN-009, or the HIV Drug Resistance Study, is a cross-sectional study to determine if women who are found to be HIV-positive during pre-screening or screening for an HIV prevention trial have evidence of drug resistant virus. This study also aims to understand the possible risk factors that contribute to drug resistance.

MTN-009, or the HIV Drug Resistance Study, is a cross-sectional study to determine if women who are found to be HIV-positive during pre-screening or screening for an HIV prevention trial have evidence of drug resistant virus. This study also aims to understand the possible risk factors that contribute to drug resistance.

With increasingly greater access to ARVs for treatment in sub-Saharan Africa and the potential that ARV-based prevention methods will be introduced in the future, it will be important to understand how tandem ARV-based treatment and prevention strategies might impact individual responses to either interventional and public health programs more broadly. By understanding the current status of HIV resistance in newly diagnosed HIV positive women of reproductive age, researchers will be able to make more informed decisions concerning future ARV-based prevention trials that target the female population. Approximately 350 HIV-infected women will be enrolled in MTN-009.

Other Study Info

Sponsor:

Division of AIDS, US National Institute of Allergy and Infectious Diseases

US National Institutes of Health

Printer-friendly version [16]
Source URL: http://www.mtnstopshiv.org/studies/1422

Links:
[1] http://www.mtnstopshiv.org/users/pkiepiela
[2] http://www.mtnstopshiv.org/users/uparikh
[3] http://www.mtnstopshiv.org/people/emailgroups/128
[4] http://www.mtnstopshiv.org/people/emailgroups/129
[5] http://www.mtnstopshiv.org/people/emailgroups/150
[6] http://www.mtnstopshiv.org/people/emailgroups/123
[7] http://www.mtnstopshiv.org/people/emailgroups/227
[8] http://www.mtnstopshiv.org/sites/50
[9] http://www.mtnstopshiv.org/sites/908
[10] http://www.mtnstopshiv.org/sites/909
[11] http://www.mtnstopshiv.org/sites/76
[12] http://www.mtnstopshiv.org/sites/1419
[13] http://www.mtnstopshiv.org/sites/52
[14] http://www.mtnstopshiv.org/sites/1420
[15] http://www.mtnstopshiv.org/node/3558
[16] http://www.mtnstopshiv.org/print/1422

Media Contacts:

Lisa Rossi -- Office: +1 412 641-8940 -- Mobile: +1 412 916-3315 -- Email: rossil@upmc.edu

Clare Collins -- Office: +1 412 641-7299 -- Mobile: +1 412 770-8643 -- Email: collcx@upmc.edu